RCP168 

RCP168 is a highly selective and affinity CXCR4 receptor antagonist (IC₅₀=5 nM). RCP168 has a stronger ability than natural chemical factors to inhibit the entry of HIV-1 (human immunodeficiency virus type 1) into host cells via CXCR4 receptors. RCP168 inhibits HIV-1 infection by blocking viral binding sites or inducing receptor internalization. RCP168 can be used to analyze the interaction between CXCR4 receptor and other chemical factor receptors^[1].

8124.52

C₃₆₅H₅₈₅N₁₀₅O₉₅S₅

d-(Leu-Gly-Ala-Ser-Trp-His-Arg-Pro-Asp-Lys)-Cys-Cys-Leu-Gly-Tyr-Gln-Lys-Arg-Pro-Leu-Pro-Gln-Val-Leu-Leu-Ser-Ser-Trp-Tyr-Pro-Thr-Ser-Gln-Leu-Cys-Ser-Lys-Pro-Gly-Val-Ile-Phe-Leu-Thr-Lys-Arg-Gly-Arg-Gln-Val-Cys-Ala-Asp-Lys-Ser-Lys-Asp-Trp-Val-Lys-Lys-Leu-Met-Gln-Gln-Leu-Pro-Val-Thr-Ala-Arg (Disulfide bridge: Cys11-Cys35,Cys12-Cys51)

d-(LGASWHRPDK)-CCLGYQKRPLPQVLLSSWYPTSQLCSKPGVIFLTKRGRQVCADKSKDWVKKLMQQLPVTAR (Disulfide bridge: Cys11-Cys35,Cys12-Cys51)

O=C(NCC(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CC3=CNC=N3)C(N[C@@H](CCCNC(N)=N)C(N4[C@@H](CCC4)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N5[C@@H](CCC5)C(NCC(N[C@@H](C(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC6=CC=CC=C6)C(N[C@@H](CC(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@H]7C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC8=O)C(N[C@@H](CSSC[C@@H](C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CC(O)=O)C(N[C@@H](CC9=CNC%10=CC=CC=C9%10)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N%11[C@@H](CCC%11)C(N[C@@H](C(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC7=O)C(N[C@@H](CC(C)C)C(NCC(N[C@@H](CC%12=CC=C(C=C%12)O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N%13[C@@H](CCC%13)C(N[C@@H](CC(C)C)C(N%14[C@@H](CCC%14)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CC%15=CNC%16=CC=CC=C%15%16)C(N[C@@H](CC%17=CC=C(C=C%17)O)C(N%18[C@@H](CCC%18)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CCC(N)=O)C(N[C@H]8CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(C)C)N

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liu D, et al. Crystal structure and structural mechanism of a novel anti-human immunodeficiency virus and D-amino acid-containing chemokine[J]. Journal of virology, 2007, 81(20): 11489-11498.  [Content Brief]